2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2290

Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Abstract Number: 2179

Comparing Observed with Expected Assessments of Osteoarthritic Pain over Time: Application of Successive Prediction to Data from the Osteoarthritis Initiative
Abstract Number: 617

Comparing Tofacitinib Safety Profile in Patients with Psoriatic Arthritis in Clinical Studies with Real-World Data
Abstract Number: 816

Comparison between Giacta Trial and a Multicenter Series of Giant Cell Arteritis Patients from Clinical Practice with Tocilizumab
Abstract Number: 2746

Comparison between IgG and IgM Type Anti-Alpha-Enolase Antibody in Patients with Behcet’s Disease According to the Disease Severity
Abstract Number: 2551

Comparison between Two Cut-Off Values of Disease Activity in Psoriatic Arthritis Index and Validation of Its Simplified Clinical Version in Patients with Psoriatic Arthritis
Abstract Number: 1502

Comparison of Classification Criteria for Sjögren’s Syndrome from 2002 and 2016 in an Incident Cohort Diagnosed 2007 to 2011 from Stockholm County Sweden
Abstract Number: 2093

Comparison of Clinical and Laboratory Features of Patients with and without Allergic Conditions in IgG4-Related Disease: A Single-Center Experience in Japan
Abstract Number: 1270

Comparison of Clinical and Serological Features of Juvenile and Adult-Onset Neuropsychiatric Lupus in Spanish Patients
Abstract Number: 2910

Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients
Abstract Number: 2161

Comparison of Clinical Characteristics between African American and Caucasian Patients with Polymyositis and Dermatomyositis and Their Response to Conventional Treatment
Abstract Number: 1840

Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial
Abstract Number: 746

Comparison of Disease Characteristics in Patients with Juvenile-Onset and Adult-Onset Progressive Systemic Sclerosis
Abstract Number: 551

Comparison of Drug Tolerability and Discontinuation Reasons between 7 Biologics in Patients with Rheumatoid Arthritis -Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER cohort)-
Abstract Number: 310

Comparison of Flexed and Extended Knee Arthrocentesis and the Role of Constant Compression

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].